Clinical Trials Browser

INDUSTRY × famitinib × Genitourinary × Clear all

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Phase 2 Unknown

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT01829841 2018-05-03

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

Phase 2 Completed

Carcinoma, Renal Cell